Last reviewed · How we verify

NCT05519345

Operant Conditioning After ACL Reconstruction

Completed NA Last updated 23 January 2024
What this trial tests

NA trial testing Operant Conditioning in Anterior Cruciate Ligament Injuries in 22 participants. Completed in 10 October 2023.

Timeline
28 December 2022
Primary endpoint
10 October 2023
10 October 2023

Quick facts

Lead sponsorUniversity of Michigan
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment22
Start date28 December 2022
Primary completion10 October 2023
Estimated completion10 October 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Michigan

Who can join

Adults 14 to 45, any sex, with Anterior Cruciate Ligament Injuries. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to examine if the changes in corticospinal function that accompany ACL reconstruction can be improved through a form of mental coaching and encouragement, known as operant conditioning.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Operant Upconditioning of the Quadriceps Motor Evoked Torque as a Means to Improve Quadriceps Function After ACL Reconstruction.
    Rodriguez KM, Palmieri-Smith RM, Krishnan C. · · 2025 · PMID 39930348 · DOI 10.1177/19417381251313775

Verify or expand the search:

Other trials of Operant Conditioning

Trials testing the same drug.

Other recruiting trials for Anterior Cruciate Ligament Injuries

Currently open trials in the same condition.

Other University of Michigan trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05519345.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing